Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Combined with Glucocorticoid in IgG4-RD with Eosinophilia
NCT05781516Unknown
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial of baricitinib in IgG4-related disease (IgG4-RD) (2 arms). Primary endpoint: Recurrence Rate of IgG4-RD at 52 weeks. Status: unknown.
02
Drugs
baricitinib
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT05781516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781516.